(Q35212500)

7 August 2017

title

Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications (English)

1 reference

7 August 2017

main subject

prostatic hypertrophy

1 reference

Michael P O'Leary

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

62

1 reference

7 August 2017

issue

3 Suppl 1

1 reference

7 August 2017

page(s)

15-23

1 reference

Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Does acute urinary retention respond to alpha-blockers alone?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Lower urinary tract symptoms suggestive of benign prostatic obstruction--what's the long-term effectiveness of medical therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

The progression of benign prostatic hyperplasia: examining the evidence and determining the risk

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Population-based studies of the epidemiology of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Introduction and Concluding Remarks

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

The aging bladder: morphology and urodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Reversible change of bladder hypertrophy due to benign prostatic hyperplasia after surgical relief of obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Effect of doxazosin on rat urinary bladder function after partial outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

A 6-month large-scale study into the safety of tamsulosin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

How do symptoms indicative of BPH progress in real life practice? The UK experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

Long-Term Risk Of Re-Treatment Of Patients Using α-Blockers For Lower Urinary Tract Symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900480-1

7 January 2021

10.1016/S0090-4295(03)00480-1

Identifiers

DOI

1 reference

7 August 2017

1 reference